Quick Takeaways
- Deep Track Capital, LP filed SCHEDULE 13G/A for Maze Therapeutics Inc. Common Stock, $0.001 par value per share (MAZE).
- Disclosed ownership: 9%.
- Date of event: 30 Jun 2025.
Deep Track Capital, LP - 30 Jun 2025 SCHEDULE 13G/A Report for Maze Therapeutics Inc. Common Stock, $0.001 par value per share (MAZE)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- MAZE
- Shares outstanding
- 43,779,490 shares
- Disclosed Ownership
- 3,948,910 shares
- Ownership
- 9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 08:48:03 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 07 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Deep Track Capital, LP disclosed 9% ownership in Maze Therapeutics Inc. Common Stock, $0.001 par value per share (MAZE) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 07 Feb 2025.
- Current filing was accepted on 14 Aug 2025, 08:48.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 9% | 3,948,910 | 0 | 3,948,910 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 9% | 3,948,910 | 0 | 3,948,910 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 9% | 3,948,910 | 0 | 3,948,910 | /s/ David Kroin | David Kroin |